EGFR and hepatotoxicity: - Phase I/II trial evaluating the combination of pembrolizumab with erlotinib or gefitinib in advanced NSCLC patients bearing EGFR mutation- Pembrolizumab plus erlotinib did not improve ORR compared with previous EGFR TKI monotherapy- Pembrolizumab plus gefitinib combination caused grade 3/4 liver toxicity in 5 out of 7 patients, resulting in premature treatment discontinuation